ClinicalTrials.gg
CompletedNCT04973566Updated Mar 4, 2025

A Study of Nipocalimab With Co-administration of Etanercept or Hydroxychloroquine in Healthy Participants

A Phase 1 interventional study of Nipocalimab and Etanercept in Healthy, sponsored by Janssen Research & Development, LLC. Completed at 1 site in Netherlands. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-04.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

The primary purpose of this study is to assess the effect of nipocalimab on the pharmacokinetic (PK) of etanercept (Part 1); and to assess the effect of hydroxychloroquine (HCQ) on total serum immunoglobin G (IgG) reduction by nipocalimab (Part 2) in healthy participants.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.

Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy based on physical examination, medical history, vital signs, and 12-lead (ECG) performed at screening. If there are any abnormalities, they must be consistent with the underlying illness in the study population or considered not and this determination must be recorded in the participant's source documents and initialed by the investigator
  • Healthy on the basis of clinical laboratory tests performed at screening (including immunoglobulin [Ig]G) and at admission to the study site. If the results of the serum chemistry panel, liver panel, hematology, or urinalysis are outside the normal reference ranges, the participant may be included only if the investigator judges the abnormalities or deviations from normal to be not clinically significant or to be appropriate and reasonable for the population under study. This determination must be recorded in the participant's source documents and initialed by the investigator
  • Good venous access in both arms
  • Participants must have heart rate of at least 50 beats per minute
  • Participant is considered eligible according to the following tuberculosis (TB) screening criteria (for Part 1 only): a) have no history of latent or active TB before screening; b) have no signs or symptoms suggestive of active TB upon medical history and/or physical examination; c) have had no recent close contact with a person with active TB; d) have a negative QuantiFERON-TB test result within 28 days prior to the administration of study intervention
  • Part 1: (BMI) greater than or equal to (>=) 18.0 to less than or equal to (\<=) 30.0 kilogram (kg)/meter (m)\^2 (inclusive), and body weight >= 50 to \<= 110.0 kg (inclusive) at the screening visit and on Day -1; Part 2: BMI >= 18.0 to \<= 30.0 kg/m\^2 (inclusive), and body weight >= 61.5 to \<= 110.0 kg (inclusive) at the screening visit and on Day -1
  • A female participant must have a negative serum (beta-human chorionic gonadotropin) test at screening and a urine pregnancy test at Day -1 prior to administration of study intervention
  • It is recommended that participants are up to date on age-appropriate vaccinations prior to screening per routine local medical guidelines. For study participants who received locally-approved (and including emergency use-authorized) coronavirus disease 2019 (COVID-19) vaccines recently prior to study entry, applicable local vaccine labeling, guidelines, and standards of care for participants receiving immune-targeted therapy should be followed when determining an appropriate interval between vaccination and study enrollment

Exclusion criteria

Exclusion Criteria:

  • Has a history of liver or renal insufficiency; cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances
  • Has a history of retinal and macular disease (only for Part 2)
  • Has shown a previous severe immediate reaction response, including anaphylaxis, to therapeutic proteins (example, monoclonal antibody [mAbs])
  • Has serum albumin levels \< 30 grams/Liter (g/L) at screening and Day -1
  • Has a history of myocardial infarction, unstable ischemic heart disease, or stroke within 12 weeks prior to screening
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Part 1: Etanercept and Nipocalimab

    Participants will receive a single subcutaneous (SC) dose of etanercept on Day 1 in Period 1 followed by single intravenous (IV) infusion of nipocalimab on Day 29, SC administration of etanercept followed by an IV infusion of nipocalimab on Day 43 and then a single dose of nipocalimab IV infusion on Day 57 in Period 2 of Part 1. There will be a wash-out period of 28 days between Day 1 of Period 1 and Day 29 of Period 2 in Part 1.

    Drug: Nipocalimab · Drug: Etanercept

  • Experimental
    Part 2 (Cohort 1): Nipocalimab

    Participants will receive a single IV infusion of nipocalimab on Day 1 in Cohort 1 of Part 2.

    Drug: Nipocalimab

  • Experimental
    Part 2 (Cohort 2): Nipocalimab and Hydroxychloroquine (HCQ)

    Participants will receive a single oral dose of HCQ film-coated tablets once daily from Day 1 to Day 22 and a single IV infusion of nipocalimab on Day 8 in Cohort 2 of Part 2.

    Drug: Nipocalimab · Drug: Hydroxychloroquine

Interventions

  • Nipocalimab will be administered as an IV infusion.

    Also known as: JNJ-80202135, M281

  • Etanercept will be administered subcutaneously.

  • HCQ will be administered orally.

06

What researchers measure

Primary outcomes

  1. Part 1: Serum Etanercept Concentration

    Serum etanercept concentration will be reported.

    Time frame: Up to Day 99

  2. Part 1: Ratio of Area Under the Concentration-time Curve (AUCR) of Etanercept

    AUCR is defined as the ratio of area under the concentration-time curve.

    Time frame: Up to Day 99

  3. Part 1: Area Under the Concentration-time Curve of Etanercept from Time Zero to Time of Last Observed Quantifiable Concentration (AUC [0-Last])

    AUC (0-last) is defined as area under the concentration-time curve of etanercept from time zero to time of last observed quantifiable concentration.

    Time frame: Up to Day 99

  4. Part 1: Area Under the Concentration-time Curve of Etanercept from Time Zero to Infinite time (AUC [0-Infinity])

    AUC (0-Infinity) is defined as area under the concentration-time curve of etanercept from time zero to infinite time, calculated as the sum of AUC (0-last) and C(last)/lambda(z) where AUC (0-last) is area under the concentration-time curve of etanercept from time zero to time of last observed quantifiable concentration and C(last) is the last observed quantifiable concentration, and lambda(z) is apparent terminal elimination rate constant.

    Time frame: Up to Day 99

  5. Part 1: Maximum Observed Concentration (Cmax) of Etanercept

    Cmax is defined as maximum observed concentration of etanercept.

    Time frame: Up to Day 99

  6. Part 1: Ratio of Maximum Observed Concentration (CmaxR) of Etanercept

    CmaxR is defined as ratio of maximum observed concentration of etanercept.

    Time frame: Up to Day 99

  7. Part 1: Time to Reach the Last Observed Measurable Analyte Concentration (Tlast) of Etanercept

    Tlast is defined as time to reach the last observed measurable analyte concentration of etanercept.

    Time frame: Up to Day 99

  8. Part 1: Time to Reach the Maximum Observed Concentration (Tmax) of Etanercept

    Tmax is defined as time to reach the maximum observed concentration of etanercept.

    Time frame: Up to Day 99

  9. Part 1: Elimination Half-life (t1/2) of Etanercept

    t1/2 is defined as elimination half-life associated with the terminal slope lambda(z) of the semilogarithmic drug concentration-time curve, calculated as 0.693/ lambda(z).

    Time frame: Up to Day 99

  10. Part 1: Total Apparent Clearance (CL/F) of Etanercept

    CL/F is total apparent clearance of etanercept following subcutaneous (SC) administration, calculated as dose/AUC (0-infinity).

    Time frame: Up to Day 99

  11. Part 1: Apparent Volume of Distribution (Vdz/F) of Etanercept

    Vdz/F is defined as apparent volume of distribution based on the terminal phase after an SC dose, calculated as dose/lambda(z)\*AUC(0-infinity).

    Time frame: Up to Day 99

  12. Part 2: Change from Baseline in Total Serum Immunoglobulin (Ig) Levels

    Change from baseline in total serum Ig levels (serum IgG and IgG subtypes) through Day 50 will be reported.

    Time frame: Baseline up to Day 50

Secondary outcomes

  1. Part 1: Number of Participants with Adverse Events (AEs)

    An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study.

    Time frame: Up to 4 months

  2. Part 1: Number of Participants with Abnormalities in Physical Examinations

    Number of participants with abnormalities in physical examinations (full and brief) will be reported. Full physical examinations will include a review of the following body systems: general appearance; thorough skin and oral mucosa evaluation; eyes, ears, nose, and throat; cardiovascular; respiratory; abdomen; peripheral pulsation; lymph nodes; neurologic; musculoskeletal; head, neck, and thyroid. A brief physical examination includes review of the following body systems: general appearance, thorough skin (including site of the injection) and oral mucosa, abdomen, respiratory, cardiovascular, any abnormalities noted on previous examinations.

    Time frame: Up to 4 months

  3. Part 1: Number of Participants with Abnormalities in Vital Sign Measurements

    Number of participants with abnormalities in vital sign measurements (body temperature \[temporal artery measurement\], pulse/heart rate, respiratory rate, blood pressure) will be reported.

    Time frame: Up to 4 months

  4. Part 1: Number of Participants with Abnormalities in Clinical Laboratory Tests

    Number of participants with abnormalities in clinical laboratory tests (serum chemistry, liver panel, hematology, and urinalysis) will be reported.

    Time frame: Up to 4 months

  5. Parts 1 and 2: Serum Nipocalimab Concentrations

    Serum nipocalimab concentrations will be reported.

    Time frame: Up to Day 99 (Part 1); up to Day 50 (Part 2)

  6. Part 1: AUCR of Nipocalimab

    AUCR is defined as the ratio of area under the concentration-time curve.

    Time frame: Up to Day 99

  7. Parts 1 and 2: AUC (0-Last) of Nipocalimab

    AUC (0-last) is defined as area under the concentration-time curve of nipocalimab from time zero to time of last observed quantifiable concentration.

    Time frame: Up to Day 99 (Part 1); up to Day 50 (Part 2)

  8. Parts 1 and 2: AUC (0-Infinity) of Nipocalimab

    AUC (0-Infinity) is defined as area under the concentration-time curve of nipocalimab from time zero to infinite time, calculated as the sum of AUC (0-last) and C(last)/lambda(z) where AUC (0-last) is area under the concentration-time curve of nipocalimab from time zero to time of last observed quantifiable concentration and C(last) is the last observed quantifiable concentration, and lambda(z) is apparent terminal elimination rate constant.

    Time frame: Up to Day 99 (Part 1); up to Day 50 (Part 2)

  9. Parts 1 and 2: Cmax of Nipocalimab

    Cmax is defined as maximum observed concentration of nipocalimab.

    Time frame: Up to Day 99 (Part 1); up to Day 50 (Part 2)

  10. Part 1: CmaxR of Nipocalimab

    CmaxR is defined as ratio of maximum observed concentration of nipocalimab.

    Time frame: Up to Day 99

  11. Parts 1 and 2: Tlast of Nipocalimab

    Tlast is defined as time to reach the last observed measurable analyte concentration of nipocalimab.

    Time frame: Up to Day 99 (Part 1); up to Day 50 (Part 2)

  12. Parts 1 and 2: Tmax of Nipocalimab

    Tmax is defined as time to reach the maximum observed concentration of nipocalimab.

    Time frame: Up to Day 99 (Part 1); up to Day 50 (Part 2)

  13. Parts 1 and 2: t1/2 of Nipocalimab

    t1/2 is defined as elimination half-life associated with the terminal slope lambda(z) of the semilogarithmic drug concentration-time curve, calculated as 0.693/ lambda(z).

    Time frame: Up to Day 99 (Part 1); up to Day 50 (Part 2)

  14. Parts 1 and 2: Total Systemic Clearance of Nipocalimab (CL)

    CL is defined as total systemic clearance of nipocalimab following an intravenous (IV) administration, calculated as dose/AUC (0-infinity).

    Time frame: Up to Day 99 (Part 1); up to Day 50 (Part 2)

  15. Parts 1 and 2: Volume of Distribution (Vdz) of Nipocalimab

    Vdz is defined as volume of distribution, based on the terminal phase after an IV dose, calculated as dose/lambda(z)\*AUC (0-infinity).

    Time frame: Up to Day 99 (Part 1); up to Day 50 (Part 2)

  16. Part 1: Number of Participants with Antibodies to Nipocalimab

    Number of participants with antibodies to nipocalimab will be reported.

    Time frame: Up to Day 99

  17. Part 2: Serum Lipid and Albumin Levels

    Participants serum lipid and albumin levels will be reported.

    Time frame: Up to Day 50

  18. Part 2: Number of Participants with Receptor Occupancy (RO) Levels of Nipocalimab

    Number of Participants with RO levels (example, neonatal Fc receptor \[FcRn\] RO in circulating monocytes) of nipocalimab will be reported.

    Time frame: Up to Day 50

07

Study locations

1 site
  • PRA Health Sciences
    Groningen, NZ 9728, Netherlands
08

References and documents

Individual participant data

Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Data sharing details ↗ · www.janssen.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2021 to primary completion in May 2022, 8 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 13, 2021
First posted
Jul 22, 2021
StartActual
Aug 31, 2021
Primary completionActual
May 27, 2022
CompletionActual
May 27, 2022
Last update
Mar 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04973566
Responsible party
Sponsor
First posted
Jul 22, 2021
Start date
Aug 31, 2021
Primary completion
May 27, 2022
Completion
May 27, 2022
Last update
Mar 4, 2025

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nipocalimab · Etanercept · Hydroxychloroquine

Start the discussion